Tango Therapeutics Inc. (TNGX)
2.73
0.11 (4.20%)
At close: Jan 15, 2025, 3:44 PM
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
The company was founded in 2017 and is based in Cambridge, Massachusetts.
Tango Therapeutics Inc.
| Country | United States |
| IPO Date | Sep 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Dr. Barbara L. Weber M.D. |
Contact Details
Address: 100 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barbara L. Weber M.D. | President, Chief Executive Officer & Director |
| Timothy Redfern | Chief Financial Officer |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Levi Garraway M.D., Ph.D. | Founder |
| Dr. Michael Palmieri Ph.D. | Head of Technical Operations |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 02, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 06, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 18, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 07, 2024 | SC 13D/A | [Amend] Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |